Temperature Check Kiosks Provide a Business’s First Line of Defense

A challenge for businesses today is how to open up safely amid a pandemic so employees and customers can once again enter the premises. Paul Harris, CEO/CTO of Aurora Multimedia Corp, and Jay Leedy, Director of Business Development at Diversified, understand this challenge.

They discussed how Diversified’s VitalSign public safety-enhancing digital signage solution provides that first level of protection to get businesses open again.

“Right now, there’s a lot of confusion in the market as to what people should be doing to deal with COVID,” Harris said. “One of the things people need to understand about temperature tablets is they are not COVID detectors, but they do detect a symptom of COVID. Typically, when people have the fever portion of it, they are spreading the disease. These tablets increase the odds in your favor that you’re not going to contaminate someone and create a spreader situation.”

Diversified’s VitalSign, which employs Aurora Multimedia Corp’s ReAX temperature check tablet technology, is a touchless system that scans for masks, checks temperatures, logs in data for future reference and can be monitored from a safe distance away from physical contact.

And VitalSign is customizable, so the messaging works for the particulars of the business and situation. With all of the additional features, it becomes more than a temperature check table, Harris said.

“It is immersed in the entire application and can be used as a security and logging device,” he said.

“We (Diversified) identified Aurora as a great fit as this market was opening up,” Leeds said. “Their ReAx engine, being JavaScript-based and with its ability to integrate with a range of third-party technologies and platforms, allowed for a lot of customization. We determined many of our users would want the ability to make changes on-the-fly themselves versus us doing that for them as a service.”

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More